Preclinically, neratinib inhibited proliferation in HER2-amplified, PIK3CA-mutant tumor cell lines [73], and inhibited tumor growth in a HER2-positive, PIK3CA-mutant patient-derived xenograft model [119]. This evidence concerns the gene ERBB2 and neoplasm.